Word: shacknai
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...company's Botox monopoly and ruled that it couldn't retain Reloxin. Guess who got the spoils? Medicis. "We lost the battle but got the product we wanted anyway," says Manny Kapur, Medicis' business director in Canada. "And we got to buy it with their money," adds Jonah Shacknai, chairman and CEO of Medicis...
...moment, though, Allergan has the competitive edge. Juvéderm will roll out in January. Medicis' Perlane won't be available until the middle of next year; Reloxin isn't expected until early 2008. Shacknai isn't too worried. He expects that market leader Restylane will hold on to its share of the filler segment and its near 90% profit margins. "We're the leading filler and have lots of pioneering products coming to market," he says. "Eventually, we will be able to meet every need for filling the face...
| 1 |